Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Court

Showing results (191-200 of 206) with videos related to

Pageof 21
Sort By:
Pharmacogenetics|July 31, 2004
Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liverHugo Girard, Michael H Court, Olivier Bernard, et al.
Antimicrobial Agents and Chemotherapy|May 14, 2014
Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6Michael H Court, Fawziah E Almutairi, David J Greenblatt, et al.
Scientific Reports|June 16, 2021
A genetic polymorphism in P2RY<sub>1</sub> impacts response to clopidogrel in cats with hypertrophic cardiomyopathyYu Ueda, Ronald H L Li, Nghi Nguyen, et al.
Progress in Clinical and Biological Research|January 1, 1990
Phase II trial of pre- and postoperative cisplatin, methotrexate and vinblastine in infiltrating bladder cancer: a three year experienceJ P Droz, M B Azab, C Theodore, et al.
Journal of Clinical Pharmacology|August 30, 2008
Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variationAwewura Kwara, Margaret Lartey, Kwamena W Sagoe, et al.
The Pharmacogenomics Journal|March 18, 2015
A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patientsS Chen, I Laverdiere, A Tourancheau, et al.
Antimicrobial Agents and Chemotherapy|December 22, 2017
Effect of Genetic Variation of <i>NAT2</i> on Isoniazid and <i>SLCO1B1</i> and <i>CES2</i> on Rifampin Pharmacokinetics in Ghanaian Children with TuberculosisAlbert Dompreh, Xiaoli Tang, Jianlin Zhou, et al.
Plos One|April 6, 2011
Evolution of a major drug metabolizing enzyme defect in the domestic cat and other felidae: phylogenetic timing and the role of hypercarnivoryBinu Shrestha, J Michael Reed, Philip T Starks, et al.
American Journal of Hematology|November 26, 2010
Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantationStacy E F Melanson, Kristen Stevenson, Haesook Kim, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|July 27, 1999
Human renal cell carcinoma xenografts in SCID mice: tumorigenicity correlates with a poor clinical prognosisE Angevin, L Glukhova, C Pavon, et al.
Pageof 21

Showing results (191-200 of 206) with videos related to

Sort By:
Pageof 21
Pharmacogenetics|July 31, 2004
Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liverHugo Girard, Michael H Court, Olivier Bernard, et al.
Antimicrobial Agents and Chemotherapy|May 14, 2014
Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6Michael H Court, Fawziah E Almutairi, David J Greenblatt, et al.
Scientific Reports|June 16, 2021
A genetic polymorphism in P2RY<sub>1</sub> impacts response to clopidogrel in cats with hypertrophic cardiomyopathyYu Ueda, Ronald H L Li, Nghi Nguyen, et al.
Progress in Clinical and Biological Research|January 1, 1990
Phase II trial of pre- and postoperative cisplatin, methotrexate and vinblastine in infiltrating bladder cancer: a three year experienceJ P Droz, M B Azab, C Theodore, et al.
Journal of Clinical Pharmacology|August 30, 2008
Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variationAwewura Kwara, Margaret Lartey, Kwamena W Sagoe, et al.
The Pharmacogenomics Journal|March 18, 2015
A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patientsS Chen, I Laverdiere, A Tourancheau, et al.
Antimicrobial Agents and Chemotherapy|December 22, 2017
Effect of Genetic Variation of <i>NAT2</i> on Isoniazid and <i>SLCO1B1</i> and <i>CES2</i> on Rifampin Pharmacokinetics in Ghanaian Children with TuberculosisAlbert Dompreh, Xiaoli Tang, Jianlin Zhou, et al.
Plos One|April 6, 2011
Evolution of a major drug metabolizing enzyme defect in the domestic cat and other felidae: phylogenetic timing and the role of hypercarnivoryBinu Shrestha, J Michael Reed, Philip T Starks, et al.
American Journal of Hematology|November 26, 2010
Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantationStacy E F Melanson, Kristen Stevenson, Haesook Kim, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|July 27, 1999
Human renal cell carcinoma xenografts in SCID mice: tumorigenicity correlates with a poor clinical prognosisE Angevin, L Glukhova, C Pavon, et al.
Pageof 21